Earnings summaries and quarterly performance for NeuroPace.
Executive leadership at NeuroPace.
Board of directors at NeuroPace.
Research analysts who have asked questions during NeuroPace earnings calls.
Frank Takkinen
Lake Street Capital Markets
5 questions for NPCE
Also covers: ANGO, AORT, AXGN +18 more
PS
Priya Sachdeva
BTIG
5 questions for NPCE
RP
Rohin Patel
JPMorgan Chase & Co.
4 questions for NPCE
Also covers: CVRX, HAE, INGN
Michael Kratky
Leerink Partners
3 questions for NPCE
Also covers: AXGN, BBNX, DXCM +6 more
Michael Polark
Wolfe Research
3 questions for NPCE
Also covers: BBNX, BSX, DXCM +13 more
Mike Kratky
Leerink Partners
3 questions for NPCE
Also covers: AXGN, DXCM, INSP +5 more
RO
Ross Osborn
Cantor Fitzgerald
3 questions for NPCE
Also covers: AXGN, CERS, CVRX +12 more
VC
Vikramjeet Chopra
Wells Fargo & Company
2 questions for NPCE
Also covers: ALGN, ATEC, CNMD +9 more
YC
Yi Chen
H.C. Wainwright & Co.
2 questions for NPCE
Also covers: ANGO, APDN, BLFS +22 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
1 question for NPCE
Also covers: ANGO, BLFS, CDXC +10 more
JP
Junwoo Park
Cantor Fitzgerald
1 question for NPCE
Also covers: CERS, PAVM, SMTI
Nelson Cox
Lake Street Capital Markets
1 question for NPCE
Also covers: AORT, AQST, CVRX +7 more
VC
Vik Chopra
Wells Fargo & Company
1 question for NPCE
Also covers: ALGN, ATEC, CNMD +8 more
Recent press releases and 8-K filings for NPCE.
NeuroPace Reports Strong Q4 2025 Revenue and Beat on EPS Estimates
NPCE
Earnings
Guidance Update
Revenue Acceleration/Inflection
- NeuroPace reported Q4 2025 revenue of $26.6 million, marking a 24% year-over-year increase, primarily driven by RNS System sales.
- The company beat earnings expectations with a loss of $0.08 per share, compared to estimates of -$0.14 to -$0.15.
- Gross margin improved to 77.4% in Q4 2025.
- NeuroPace provided Q1 2026 revenue guidance of $21–22 million.
- Analysts and data providers highlight financial risks, including an Altman Z-Score of -2.65 (in the distress zone), debt-to-equity of 3.84, and ROE of -149.8%.
3 days ago
NeuroPace Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Advances IGE Indication
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace reported strong Q4 2025 revenue of $26.6 million, a 24% year-over-year increase, primarily driven by RNS System revenue of $22.4 million, up 26%. The company achieved its second consecutive quarter of positive adjusted EBITDA at $900,000.
- For the full year 2025, total revenue grew 25% to $100 million, with RNS System sales also growing 25%. Gross margin improved to 77.2% for the full year, with RNS gross margin at 81.9%.
- The company reiterated its full year 2026 revenue guidance of $98 million-$100 million, reflecting 20%-22% underlying RNS growth and excluding any contribution from idiopathic generalized epilepsy (IGE) regulatory approval or DIXI Medical. For Q1 2026, revenue is expected to be $21 million-$22 million.
- NeuroPace submitted its PMA supplement for an expanded indication in idiopathic generalized epilepsy (IGE) to the FDA on December 15th, with the FDA accepting the submission and initiating a 180-day review clock. Additionally, the company expects SeizureID approval in the first half of 2026.
3 days ago
NeuroPace Announces Strong Q4 and Full Year 2025 Results, Reiterates 2026 Guidance, and Provides IGE Regulatory Update
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% year-over-year increase, contributing to full year 2025 revenue of $100 million, a 25% increase.
- The company achieved its second consecutive quarter of positive adjusted EBITDA in Q4 2025, reaching $900,000, and reported $61.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
- NeuroPace reiterated its full year 2026 revenue guidance of $98 million-$100 million, reflecting 20%-22% underlying RNS growth, and expects Q1 2026 revenue between $21 million and $22 million. This guidance excludes contributions from idiopathic generalized epilepsy (IGE) regulatory approval, service revenue, or DIXI Medical.
- The PMA supplement for an expanded indication in IGE was submitted to the FDA on December 15, 2025, and accepted for review, initiating a 180-day clock.
- Product development is advancing with NeuroPace AI tools like Seizure ID (expected approval H1 2026) and RNS remote care, while the DIXI Medical commercial partnership concluded on December 31, 2025.
3 days ago
NeuroPace Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Outlook, and Advances IGE Indication
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace delivered strong quarterly revenue of $26.6 million in Q4 2025, representing 24% year-over-year growth, contributing to a full-year 2025 revenue of $100 million, up 25%.
- The company achieved its second consecutive quarter of positive adjusted EBITDA in Q4 2025, reaching $900,000, and generated positive cash flow.
- NeuroPace reiterated its full-year 2026 revenue guidance of $98 million-$100 million, reflecting 20%-22% underlying RNS growth on a continuing operations basis, excluding contributions from idiopathic generalized epilepsy (IGE) or DIXI Medical.
- A PMA supplement was submitted to the FDA for an expanded indication of the RNS System in IGE, which has been accepted for a 180-day review.
- The company expects SeizureID, an AI-enabled tool, to be approved in the first half of 2026, and is advancing RNS remote care capabilities.
3 days ago
NeuroPace Reports Strong Q4 and Full Year 2025 Financial Results and Reiterates 2026 Outlook
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace reported total revenue of $26.6 million for Q4 2025, marking a 24% increase year-over-year, and $100.0 million for the full year 2025, a 25% increase from 2024.
- The company achieved Adjusted EBITDA of $0.9 million in Q4 2025, its second consecutive quarter of positive Adjusted EBITDA, and maintained a strong liquidity position with $61.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
- NeuroPace reiterated its full year 2026 total revenue guidance of $98 million to $100 million, reflecting an anticipated 20% to 22% growth in core RNS® revenue from existing indications.
- Strategic developments include the submission of a PMA-S to the FDA for an expanded RNS System indication for idiopathic generalized epilepsy (IGE) and the submission of Seizure ID™, an AI-powered tool, for FDA review.
3 days ago
NeuroPace Reports Strong Q4 and Full Year 2025 Results, Reiterates 2026 Outlook
NPCE
Earnings
Guidance Update
Revenue Acceleration/Inflection
- NeuroPace reported Q4 2025 total revenue of $26.6 million, representing 24% growth compared to Q4 2024, and full-year 2025 total revenue of $100.0 million, a 25% growth over 2024.
- The company achieved $0.9 million in Adjusted EBITDA for Q4 2025, marking its second consecutive quarter of positive Adjusted EBITDA, and improved its total gross margin to 77.4% in Q4 2025.
- For full year 2026, NeuroPace reiterated guidance expecting total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue, and a non-GAAP gross margin of 81.5% to 82.5%.
- Strategic advancements include the submission of a PMA-Supplement to the FDA for an expanded RNS System indication for idiopathic generalized epilepsy (IGE), with potential approval in mid-2026, and favorable reimbursement updates for CY 2026.
3 days ago
NeuroPace Reports 2025 Performance and Provides 2026 Guidance
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace reported 2025 revenue of $100 million, marking a 25% increase year-over-year.
- For fiscal year 2026, the company anticipates revenue between $98 million and $100 million, with RNS revenue growth projected at approximately 20-22%.
- The company forecasts a Non-GAAP Gross Margin of 81.5-82.5% and an Adjusted EBITDA of ($9)-($10) million for FY26.
- NeuroPace is targeting a significant market opportunity, addressing 1.2 million drug-resistant epilepsy (DRE) patients in the U.S., which represents a >$55 billion market.
- The RNS System demonstrates strong clinical efficacy, achieving an 82% median seizure reduction at 3 years in post-approval studies, which is higher than other neuromodulation therapies.
3 days ago
Brain Computer Interface Market Projected for Significant Growth
NPCE
New Projects/Investments
Revenue Acceleration/Inflection
Product Launch
- The global brain computer interface (BCI) market was valued at US$ 2.84 billion in 2024 and is expected to reach US$ 11.20 billion by 2033, growing at a CAGR of 16.43% from 2025 to 2033.
- Growth is driven by precision medical innovations, industrial-grade neurotechnology, and non-medical use cases, with 73% of 2024's US$ 2.1 billion BCI funding targeting non-medical applications.
- Key advancements include NeuroPace’s RNS System achieving a 40% reduction in seizure frequency, Honeywell’s Cortex N3 headsets cutting fatigue-related incidents by 27%, and non-invasive BCI systems commanding an 86% market share due to innovations like Neurable's Enten headset achieving 95% mental command accuracy.
- The Asia Pacific region is experiencing rapid growth, anchored by China's US$ 1.4 billion Brain Project and supported by technological advancements such as Huawei's graphene-based sensors, which cut EEG manufacturing expenses by 30%.
Jan 22, 2026, 6:24 PM
NeuroPace Reports Strong 2025 Results and Provides 2026 Guidance
NPCE
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- NeuroPace achieved a significant milestone in 2025 with its first-ever $100 million in revenue, marking 25% year-on-year growth, primarily driven by its RNS System which also grew 25% to $81.7 million and delivered 77.2% gross margins.
- For 2026, the company projects revenue of $98-$100 million, with RNS revenue growth of 20%-22% and an anticipated increase in gross margins to 81%-82%.
- Strategic growth initiatives include the recent PMA supplement submission to the FDA for idiopathic generalized epilepsy (IGE) patients and ongoing development for pediatric and Lennox-Gastaut indications, though 2026 guidance does not include revenue from potential IGE approval.
- The company is developing AI algorithms leveraging its over 24 million individualized EEG recordings to enhance therapy effectiveness and efficiency, and reported an increase in its cash balance from $60 million in Q3 2025 to $61 million in Q4 2025.
- NeuroPace remains confident in its ability to achieve cash flow break-even by 2027.
Jan 14, 2026, 11:00 PM
NeuroPace Reports Preliminary FY2025 Results and Provides FY26 Guidance
NPCE
Earnings
Guidance Update
New Projects/Investments
- NeuroPace reported preliminary unaudited total revenue of ~$100 million for FY2025, representing +25% YoY growth, with RNS Revenue at ~$81.7 million (+25% YoY growth) and a gross margin of ~77.2%. For Q4 2025, total revenue was ~$26.6 million (+24% YoY growth).
- The company provided FY26 guidance for revenue between $98 million and $100 million, with RNS Revenue growth of ~20-22% and a projected gross margin of ~81-82%.
- NeuroPace is pursuing market expansion into generalized epilepsy and pediatrics, with a PMA-S submitted to the FDA in Q4 2025 for indication expansion in idiopathic generalized epilepsy (IGE).
- The company is also focused on advancing its AI ecosystem built on a proprietary iEEG dataset, developing a robust product pipeline including next-gen PDMS and AI-Powered ADAPT, and expanding access through community channels.
Jan 14, 2026, 11:00 PM
Quarterly earnings call transcripts for NeuroPace.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more